In the general population, it has been estimated that 1.5% of people have ≥1 Tarlov cysts, with about 13% of those being symptomatic. Despite a range of options for treatment, there is debate about when, and how to optimally treat individuals with Tarlov cysts among clinicians, and among policy decision makers.
To summarize the current evidence on surgical treatment of Tarlov cysts.
A systematic review was completed.
Nine databases were searched. Abstracts and full-texts were assessed by 2 reviewers. To be included, studies had to assess safety, efficacy, or effectiveness of treating Tarlov cysts, had to be written in English or French, and had to be a randomized, quasi-randomized, observational cohort, case control, or case series design including ≥2 participants. Logistic regression analysis was undertaken on the patient-level data collected to assess the association of patient and cyst characteristics on treatment success.
In total, 31 studies were included in this systematic review; all were case series. Among the 646 participants included in these 31 studies, 210 experienced complete resolution of symptoms (32%), 327 had partial resolution (50%), 106 did not have any improvement or worsening of symptoms (16%), and 3 had their symptoms worsen after surgery (0.4%). A number of adverse events were reported after surgery; however, all were temporary. The analysis of 49 patients with data on cyst size resulted in the odds of complete resolution of symptoms being lower for patients with larger cysts (odds ratio=0.53, P-value=0.107) although this finding is not statistically significant. For those with a cyst >1.5 cm the odds of complete resolution were (odds ratio=0.36, P-value=0.190) compared with those with a cyst <1.5 cm.
The evidence suggests that surgery for symptomatic Tarlov cysts may be an effective option for partially or completely relieving symptoms. Contrary to previous findings larger cysts were not associated with completely relieving symptoms.
*Department of Community Health Sciences, University of Calgary
†O’Brien Institute for Public Health, Calgary
‡Institute of Health Economics, Edmonton, AB, Canada
Supported by a financial contribution from Alberta Health. The views expressed herein do not necessarily represent the official policy of Alberta Health.
L.E.D., F.C., S.C., D.L.L., T.N., L.S., and E.S.: design of the study, interpretation of the data, review of manuscript, approval of manuscript. L.E.D., S.C., D.L.L., and L.S.: collection of data, management of data. L.E.D., S.C., and E.S.: analysis of data. L.E.D., F.C., T.N., L.S., and E.S.: preparation of manuscript.
The authors declare no conflict of interest.
Reprints: Eldon Spackman, PhD, Teaching Research and Wellness Building, 3280 Hospital Drive NW, Calgary, AB, Canada T2N 4N1 (e-mail: email@example.com).
Received March 15, 2017
Accepted July 19, 2017